Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | ALB | P02768 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | TK1 | P04183 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311439 | 1.00 | LMNA (0.52) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL6754526 | 1.00 | LMNA (0.52) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL6312398 | 1.00 | LMNA (0.52) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL2056628 | 0.89 | LMNA (0.51) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL14664272 | 0.86 | LMNA (0.53) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL14664299 | 0.86 | LMNA (0.53) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL14664273 | 0.86 | LMNA (0.53) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL6394877 | 0.85 | LMNA (0.52) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL5086587 | 0.85 | LMNA (0.52) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL6889312 | 0.85 | LMNA (0.52) | LMNAALBBLMALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240220911-A1 | SYSTEMS AND METHODS FOR LAST-MILE DELIVERY ASSIGNMENT | WALMART APOLLO, LLC | 2024-07-04 | — | — | US | claimed |
| US-20250086816-A1 | INFORMATION PROCESSING APPARATUS, GENERATION METHOD, AND COMPUTER PROGRAM PRODUCT | KABUSHIKI KAISHA TOSHIBA (JP) | 2025-03-13 | — | — | US | disclosed |
| CN-222597432-U | Oil gas pipeline detects positioner | 广东石油化工学院 | 2025-03-11 | — | — | CN | disclosed |
| US-20240220911-A1 | SYSTEMS AND METHODS FOR LAST-MILE DELIVERY ASSIGNMENT | WALMART APOLLO, LLC | 2024-07-04 | — | — | US | disclosed |
| US-6949522-B2 | β-2′- or 3′-halonucleosides | PHARMASSET, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050119286-A1 | BETA-2'-OR 3'-HALONUCLEOSIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-02 | — | — | US | disclosed |
| EP-1478322-A2 | Beta-2'-OR 3'-HALONUCLEOSIDES | Pharmasset Limited (BB) | 2004-11-24 | — | — | EP | disclosed |
| US-6784161-B2 | VIRICIDES FOR HEPATITIS C | BIOCHEM PHARMA, INC. (CA) | 2004-08-31 | — | — | US | disclosed |
| WO-2003000200-A2 | β-2'-OR 3'-HALONUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-01-03 | — | — | WO | disclosed |
| US-20020019363-A1 | Method for the treatment or prevention of flavivirus infections using nucleoside analogues | VIROCHEM PHARMA INC. (CA) | 2002-02-14 | — | — | US | disclosed |
| US-5846516-A | Perfluoroalkylated amphiphilic phosphorus compounds: preparation and biomedical applications | ALLIANCE PHARMACEUTIAL CORP. (US) | 1998-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019363-A1 | Method for the treatment or prevention of flavivirus infections using nucleoside analogues | NUDT1, HAVCR2, SLC28A1 | LMNA 1516/4885ALB 1932/4885BLM 825/4885 |
| US-20050119286-A1 | BETA-2'-OR 3'-HALONUCLEOSIDES | MKI67, EBP, PCNA | LMNA 211/4885ALB 3948/4885BLM 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.